BioCryst Pharmaceuticals, Inc. 4505 Emperor Boulevard Suite 200 Durham,
NC 27703 United States - Map Phone: 919-859-1302 Fax: 919-859-1314 Website: http://www.biocryst.com
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. Its pre-clinical compounds include BCX4161, an oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a RNA dependent-RNA polymerase inhibitor for treating Filoviruses. The company has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Key Statistics
| |
| BioCryst Pharmaceuticals, Inc.’s ISS Governance QuickScore as of May 1, 2013 is 6. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 7; Compensation: 6. | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Mr. Jon P. Stonehouse ,
52 Chief Exec. Officer, Pres and Exec. Director | 474.00K | 0.00 | Mr. Thomas R. Staab II, CPA,
45 Chief Financial Officer, Principal Accounting Officer, Sr. VP and Treasurer | 387.00K | 0.00 | Dr. William P. Sheridan MBBS,
58 Chief Medical Officer and Sr. VP | 417.00K | 0.00 | Dr. Yarlagadda S. Babu Ph.D.,
60 VP of Drug Discovery | 342.00K | 281.00K | Ms. Alane P. Barnes ,
VP, Gen. Counsel and Corp. Sec. | N/A | N/A |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|